Imugene Ltd has released a press release.
Two Additional Complete Responses in azer-cel Ph1b trial
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Imugene
- Notice of Extraordinary General Meeting/Proxy Form
- Azer-cel Granted FDA Fast Track Designation in Blood Cancer
- S&P DJI Announces March 2025 Quarterly Rebalance
- Imugene Granted India Patent for Oncolytic Virotherapy CF33
- Imugene OnCARlytics Patent Allowance in China
Later from Imugene
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Capital Raising Presentation
- Appendix 4E and Annual Report
- Final Share Purchase Plan Allotment
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene